19 results
8-K
EX-99.2
1ity6c
13 Feb 24
Results of Operations and Financial Condition
4:10pm
8-K
EX-99.1
bl88am 6q
13 Feb 24
Results of Operations and Financial Condition
4:10pm
8-K
EX-2.1
yc1af66zp87vs9l9kcp
6 Feb 24
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
8:05am
8-K
EX-10.2
yeg2iyna 2enroxyg29
29 Dec 23
Departure of Directors or Certain Officers
5:00pm
10-K
xbifrke7
25 Mar 21
Annual report
5:01pm
10-K
EX-10.27
3fvqkamb
25 Mar 21
Annual report
5:01pm
424B4
gs0f aor6g8hnh03rr
5 Oct 20
Prospectus supplement with pricing info
5:10pm
S-1/A
eyrai4
24 Sep 20
IPO registration (amended)
7:18am
S-1
bcabgsq 5w
9 Sep 20
IPO registration
4:19pm
S-1
EX-10.13
kgqa7
9 Sep 20
IPO registration
4:19pm
S-1
EX-10.18
3287t
9 Sep 20
IPO registration
4:19pm
DRS
n5v 816zk
12 Aug 20
Draft registration statement
12:00am
- Prev
- 1
- Next